AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02852226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Characteristics of women who enroll
Description: The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.
Study NCT02852226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: referral sources of women who enroll
Description: Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
Study NCT00811252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules; daily; orally
Study NCT00811252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets; daily; orally
Study NCT00811252 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: encapsulated tablets; daily; orally
Study NCT03420638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunct Exparel (bupivacaine liposome suspension 1.3%)
Description: After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\] i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension 1.3% (13.3 mg/mL) on each side.
Study NCT03420638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
Study NCT03420638 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
Study NCT03456011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Battlefield Acupuncture
Description: Battlefield Acupuncture gold semi permanent needles
Study NCT05293418 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: data collection from medical records and the microbiological surveillance system of the enrolled patients
Study NCT03014648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
Study NCT03553173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: So-Lo-Mo
Description: So-Lo-Mo is an innovative intervention based on mobile technologies and its capacity to trigger behavioral changes. In this sense, the App is a complement to pharmacological therapies to quit smoking providing personalised motivational messages, physical activity monitoring, lifestyle advices and distractions (mini-games) to help pass the cravings. The main objective of this App is to improve patient's adherence to the smoking cessation process making use of behavioral techniques in the form of motivational messages and/or Short Message Service (SMS).
Study NCT03500341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00014
Description: Noninvasive pulse oximeter sensor
Study NCT04394962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Patients randomized to the study group, will be provided with the VR headset and sensors. The VR exposure will take place before the ET procedure, during their routine pre-transfer waiting period, in a private room. The patient will be able to choose between three different calming VR environments (3 scenes: beach sunset, palm tree patio or redwood forest) and will be exposed to the chosen VR environment for a continuous duration of 15-30 minutes. The VR exposure will be passive, and the patient can control her observation inside the environment by herself, simply by moving her head. During this period, at any time and for any reason, the patient can discontinue the use of the VR session simply by self-removing the helmet
Study NCT02017262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management group
Description: 8 weekly sessions of group self-management
Study NCT02017262 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
Study NCT03917147 — intervention group
Intervention type: PROCEDURE
Intervention: Office Hysteroscopy
Description: Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.
Study NCT02169063 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon-11 acetate
Description: Given IV
Study NCT02169063 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 sodium fluoride
Description: Given IV
Study NCT02169063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo 11C-acetate and 18F-fluoride PET
Study NCT02169063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01593852 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Advanced image processing
Description: Acquisition of x-ray images with reduced X-ray dose and advanced image processing
Study NCT01593852 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Regular image processing
Description: Acquisition of x-ray images with regular X-ray dose and regular image processing
Study NCT04649593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Samarin
Description: Half of the group with a high AFL value will have a glass of Samarin to drink
Study NCT03590808 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccination
Description: Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
Study NCT03590808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Description: Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
Study NCT03059186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude diary
Description: The intervention involves keeping a record of three things that the individual feels grateful for during that day.~This can be completed daily, and for the purpose of this study will be completed every evening for the duration of one week.
Study NCT03289884 — intervention group
Intervention type: OTHER
Intervention: MRI scan (not involving ionising radiation)
Description: The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
Study NCT03289884 — intervention group
Intervention type: OTHER
Intervention: Ultrasound scan (not involving ionising radiation)
Description: The US scan will be conducted by a nominated researcher
Study NCT03289884 — intervention group
Intervention type: OTHER
Intervention: Ex vivo MRI scan of cyst fluid sample
Description: The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
Study NCT03289884 — intervention group
Intervention type: OTHER
Intervention: Aspiration of cyst fluid
Description: For patients undergoing surgery/radiologically guided aspiration the aspiration will be performed by a surgeon (at the Royal Free Hospital) or radiologist
Study NCT03289884 — intervention group
Intervention type: OTHER
Intervention: Blood test for confirmation of serum IgG levels consistent with hydatid infection
Description: The blood sample will be drawn by a member of the clinical team
Study NCT01115647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-Use Therapeutic Food (RUTF)
Description: A Ready-to-Use Therapeutic Food (RUTF), locally produced in Burkina Faso. The RUSF will be nutritionally characterized by chemical analysis (macronutrients, amino acids, vitamins A, C, D, E, B12, thiamin, riboflavin, niacin, calcium, iron, zinc, copper, selenium) and will be analyzed for macronutrients and energy density. All analysis methods are either based on the Official Methods of Analysis of AOAC International or in-house validated analytical methods. The pilot production phase and Hazard Analysis of Critical Control Points (HACCP) risk inventory of the production process will be performed by a food technologist from the Department of Food safety and Food quality, Ghent University.
Study NCT01115647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CBS++
Description: CSB is a low-cost combination of a cereal and a legume sometimes fortified with micronutrients. However, it presents shortcomings such as too many anti-nutrients, suboptimal micronutrient content, high bulk and viscosity. The World Food Program has recently proposed an enhanced CSB, named CSB++, which is prepared from heat treated maize and de-hulled soya beans, sugar, dried skim milk, refined soya bean oil, vitamins and minerals.
Study NCT02916329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907
Description: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
Study NCT01115647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCC
Description: Child-Centred dietary Counselling (CCC). Although educational/behavioral interventions can be effective to improve child growth, there is little evidence of their effectiveness for MAM. Moreover, evidence from Africa is inexistent. Currently, the main management of MAM consists of giving nutritional advice to the caretakers, but mothers of MAM children are given the same general dietary advice as mothers of well-nourished children. A more efficient, child-centred approach is therefore proposed, by adapting the counselling to the needs of the family, developing a more child-centred approach, by providing operational recommendations for MAM children and providing an adequate follow-up post-treatment.
Study NCT01013077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optive
Description: Use a minimum of 2 drops per day for 1 month.
Study NCT03553173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological advice
Description: Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
Study NCT00785941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 1~6 mg/kg I.V., once every other week for 4 weeks
Study NCT01013077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soothe
Description: Use a minimum of 2 drops per day for 1 month.
Study NCT01013077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Emulsion
Description: Use a minimum of 2 drops per day for 1 month.
Study NCT04230525 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: non invasive whole body bioimpedence system
Description: Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia. The whole-body bioimpedance method will be used to monitör the hemodynamic changes non invasively. This method can evaluate such as cardiac output, cardiac index, stroke volüme, stroke index, stroke volüme variations, cardiac reserve, etc. Parameters with a completely noninvasive method by using only electrots. The device consists of a laptop, a software which calculates cardiac parameters and two electrodes. The measurement is done by the following process: one of these electrodes, which looks like ECG electrodes, is stuck to the wrist and the other one to the opposite ankle or each one to two wrists.
Study NCT00178802 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)
Description: 5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days~Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour~Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily~Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol
Study NCT01327391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: On line Hemodiafiltration
Description: 3 sessions/week; 3-4 hours per session
Study NCT01327391 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemodialysis
Description: 3 sessions/week; 3-4 hours per session; high flux dialyzers
Study NCT04183673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: 5 days per week, 3 weeks, sessions of usual rehabilitation
Study NCT00785941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 2~10 mg/kg I.V., once every other week for 4 weeks
Study NCT00785941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 3~15 mg/kg I.V., once every other week for 4 weeks
Study NCT00785941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 4~21 mg/kg I.V., once every other week for 4 weeks
Study NCT00785941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 5~27 mg/kg I.V., once every other week for 4 weeks
Study NCT05299450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet It shots
Description: In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/
Study NCT03553173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological advice
Description: Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
Study NCT05299450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.
Study NCT01233167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: clopidogrel 75 mg po per day for 12 months
Study NCT01233167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 75mg po per day for 12 months
Study NCT03553173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Pill
Description: Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.
Study NCT01233167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel and placebo
Description: clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
Study NCT03553173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Pill
Description: Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.
Study NCT03553173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Pill
Description: Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.
Study NCT03553173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Pill
Description: Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.
Study NCT03848819 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VitaBreath device
Description: The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
Study NCT03848819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaBreath device
Description: The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
Study NCT05448079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual counseling according to the PLISSIT model, randomized pretest-posttest
Description: experimental and control ,a randomized pretest-posttest study to examine
Study NCT02363205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet-administrated CBT-Treatment
Description: Guided internet-delivered CBT with chat sessions
Study NCT01147783 — intervention group
Intervention type: OTHER
Intervention: CT, MRI
Study NCT01486264 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin®
Description: Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
Study NCT02980614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4D flow imaging
Description: To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
Study NCT01779609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Study NCT01779609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01779609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise training program of 8 weeks, for 3x/week
Study NCT01779609 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Supervised exercise training program of 8 weeks, for 3x/week
Study NCT01779609 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Supervised exercise training program of 8 weeks, for 3x/week
Study NCT00367757 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablate AF triggers via PVI
Description: Trigger-based ablation guided by pulmonary vein antrum isolation
Study NCT00367757 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Substrate via CFAEs
Description: Substrate-based ablation using an approach targeting CFAEs
Study NCT00367757 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Combined approach for AF ablation
Description: Combined trigger and substrate based approach